Filing Flows › Inhibrx Biosciences (INBX) › Q4 2024 › vs Q4 2023
Inhibrx Biosciences (INBX) Q4 2024 vs Q4 2023 (year over year)
Inhibrx Biosciences's revenue fell $1.5M (-94%) from $1.6M in Q4 2023 to $100K in Q4 2024.
Inhibrx Biosciences, Q4 2024: revenue $100K (-94% year over year), net loss $47.9M, operating cash flow −$43.7M. The chart draws each line against Q4 2023, the increases inside each band.
Every line
| Line | Q4 2024 | Q4 2023 | Change | % |
|---|---|---|---|---|
| Revenue | $100K | $1.6M | −$1.5M | -94% |
| Other income, net | $2.1M | −$5.3M | $7.4M | — |
| Net loss | $47.9M | $93.6M | −$45.7M | -49% |
| Costs & expenses | $50.0M | $95.2M | −$45.2M | -47% |
| Operating costs | $50.0M | $89.9M | −$39.9M | -44% |
| Research & development | $33.4M | $82.1M | −$48.7M | -59% |
| General & admin | $16.7M | $7.8M | $8.8M | +113% |
| Operating cash sources | $47.9M | $93.6M | −$45.7M | -49% |
| Depreciation & amortization | $689K | $298K | $391K | +131% |
| Share-based compensation | $3.0M | $6.4M | −$3.4M | -54% |
| Working capital & other | $474K | $30.1M | −$29.6M | -98% |
| Cash used in operations | $43.7M | $56.8M | −$13.1M | -23% |
| Net loss absorbed | $47.9M | $93.6M | −$45.7M | -49% |
Questions
How much did Inhibrx Biosciences's revenue grow year over year in Q4 2024?
Inhibrx Biosciences's revenue fell $1.5M (-94%) from $1.6M in Q4 2023 to $100K in Q4 2024.